FINHUB Insights

GILD · Q2 FY25 · Apr 1 – Jun 30, 2025

Gilead Sciences Q2 FY25: where the revenue came from and where it went

Gilead Sciences Q2 FY25: revenue $7.1B (+2% year over year). Net profit $2B. Largest cohort HIV Products Biktarvy $3.5B. The whole income statement as a sankey diagram from the SEC filing.

Period
Apr 1 – Jun 30, 2025
Reported
Aug 7, 2025 10-Q
Sankey diagram of Gilead Sciences's income statement for Q2 FY25: revenue of $7.1 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$7.1B +2% year over year
Gross profit$5.6B 79% margin
Operating profit$2.5B 35% margin
Net profit$2B 28% margin

The numbers

All figures in billions of U.S. dollars, for Q2 FY25 (period ends Jun 30, 2025).
ItemValueShare of revenueYear over year
Revenue 7.1 100% +2%
HIV Products Biktarvy 3.5 49% +9%
Other 1.1 15%
HIV Products Descovy 0.7 10% +35%
Yescarta 0.4 6% −5%
HIV Products Genvoya 0.4 6% −14%
Trodelvy 0.4 6% +14%
Liver Disease Products Sofosbuvir… 0.3 4% −28%
HIV Products Odefsey 0.3 4% −5%
Cost of revenue−1.521%
Gross profit5.679% margin+1pp
SG&A−1.419%−1pp
Other−1.725%+0pp
Operating profit2.535% margin−3pp
Tax−0.5
Net profit228%+4pp
Filing on EDGAR More quarters of GILD

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters